Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs but also capable of extrapulmonary involvement. It remains a major global health burden.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
India launches ₹10,000 crore Biopharma SHAKTI initiative to transform from generics manufacturing to innovation-led biologics leadership. The national mission aims to capture 5% of global biopharmaceutical market while addressing structural challenges in drug discovery and AI adoption.
A vaccine and two novel tuberculosis treatments are advancing through Phase III trials, marking renewed momentum in TB research. Tuberculosis claims over 1.25 million lives annually with 10.6 million new cases in 2023, while current treatments face challenges of high pill burden, toxicity, and rising resistance.
The World Health Organization has recommended new portable TB diagnostic tests that deliver results in under an hour, while researchers developed an inhalable nanoparticle treatment that could replace daily pills. TB remains the world's deadliest infectious disease, killing 1.2 million people in 2024 despite being preventable and curable.
Researchers have developed an inhalable nanoparticle system for delivering rifampin directly to the lungs, potentially reducing tuberculosis treatment from daily to once-weekly dosing while lowering side effects and improving drug effectiveness.
BioVersys has dosed the first patient in a Phase 2b trial evaluating alpibectir-ethionamide (AlpE) in combination with first-line TB drugs, following promising Phase 2a results published in the New England Journal of Medicine.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Healthcare systems worldwide are addressing polypharmacy as a major public health issue, with new guidance emphasizing person-centered medication reviews and risk mitigation strategies across multiple clinical settings including infectious disease care.
Vir Biotechnology is set to report Q4 2025 earnings on Feb 23, 2026, with analysts expecting revenue of $19.91-$23.18 million and a loss of $0.41-$0.50 per share, marking a 61% year-over-year revenue increase.
Obesity contributes to about 1 in every 4 infectious disease deaths in the United States and 1 in 10 globally, according to a major study. People with obesity face 70% higher risk of hospitalization or death from infections, with risk tripling at severe obesity levels.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07595042 |
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07485868 |
Development of a Clinical-epidemiological Score Predictive of Tuberculosis. |
NOT_YET_RECRUITING | |
| NCT07484490 |
Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis |
RECRUITING | NA |
| NCT07479030 |
A Home-Based Approach to Tuberculosis Preventive Treatment Management |
NOT_YET_RECRUITING | NA |
| NCT07459569 |
Diagnostic Performance and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy in Diagnosing Tuberculous Mediastinal Lymphadenitis: a Randomised Controlled Trial |
NOT_YET_RECRUITING | NA |
| NCT07440160 |
Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol |
ACTIVE_NOT_RECRUITING | NA |
| NCT07386912 |
Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE - |
NOT_YET_RECRUITING | |
| NCT07332325 |
STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07312266 |
Questioning the Epidemiology of Asymptomatic TB |
RECRUITING | |
| NCT07293455 |
Evaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia |
NOT_YET_RECRUITING | NA |
